Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pragmatic EMR Trials for Neurological Disorders
NCT02670161Phase 4Enrolling by invitation
- Sponsor
- Endeavor Health
- Start
- May 2016
- Primary completion
- Dec 2026
- Modality
- Reversible Covalent Inhibitors, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lamotrigine, levetiracetam, valproic acid, donepezil, rivastigmine and 17 more in brain tumor, epilepsy, Mild Cognitive Impairment (MCI) and 7 more (3 arms), sponsored by Endeavor Health. Primary endpoints: Survival free of discontinuation or alternative prevention drug at 6 months, Survival free of disability measured by FAQ score 9+ at 1 year and 1 more. Started May 2016; status: enrolling by invitation.
02
Drugs
lamotriginelevetiracetamvalproic aciddonepezilrivastigmine
03
Conditions
brain tumorepilepsyMild Cognitive Impairment (MCI)migrainetraumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02670161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670161.